NEW YORK (GenomeWeb News) - Emory University and Ohio State University are pulling together their biomedical and biotechnology resources to start a personalized medicine partnership that will focus on genomics, clinical trials, bioinformatics, technology transfer, and environmental and behavioral research, Emory said yesterday.
The initiative, called the Alliance for Predictive and Personalized Health, is aimed at “transforming health care into a more patient-centered system that integrates scientific breakthroughs in genomics and molecular biology with advances in communications and information technology,” the universities said in a statement.
The effort builds on several initiatives already underway at the two institutes. In 2005, Emory teamed with Georgia Tech to start a Predictive Health Institute that focuses on genetic and protein biomarkers and a Center for Health Discovery and Well-Being that serves as "a clinical testing ground" for predictive medicine and translational research.
The same year, Ohio State started its Center for Personalized Health Care, which combines bioinformatics, genomics, imagine and clinical trials.
Under the auspices of the Alliance for Predictive and Personalized Health, the universities plan to partner in biomarker research, biobanking, cancer genetics, autoimmune imaging, and other medical areas.
The schools also plan to conduct clinical trials and study phenotyping and biomarkers, as well as the legal issues, and the education and training involved in personalized medicine.
Bioinformatics research will involve data integration, biomedical informatics and high-throughput computing.
The partners also plan to focus on technology transfer and research and IP management, as well as technology research and development focused on databases, biobanks and biomarkers.
The effort also will entail studies of environmental risks and behavioral science and medicine, nutrition and legal, ethical and health policy.
Ohio State's Daniel Semak, executive director for the CPHC, said in a statement that the partnership is "a tremendous opportunity" to share resources in order to "take advantage of this amazing convergence of scientific and technological discovery, and develop a new model of health care that is tailored to the individual patient for prediction, prevention and treatment."